FDA Rejects New Drug Sparlon After Link To SJS

The Food and Drug Administration recently rejected approval of Cephalon Inc.’s newest drug Sparlon, an attention deficit/hyperactivity disorder drug, after it was found to trigger Stevens-Johnson Syndrome (SJS), a serve allergic reaction that often times is fatal. The debilitating drug induced reaction kills thousands of consumers each year and was determined to be too great a risk for the public at large. Finally, the FDA is taking a firm stand on new drugs related to and triggering SJS. Now if they would help facilitate the removal of other dangerous drugs connected to SJS already on the market we all would be a lot safer when it comes to dealing with this tragic allergic reaction.